Benzinga | Aug 10, 2020 06:34AM EDT

Sage Therapeutics Q2 EPS $(2.63) Beats $(2.66) Estimate, Sales $1.09M Beat $890.00K Estimate

Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.63) per share which beat the analyst consensus estimate of $(2.66) by 1.13 percent. This is a 19.82 percent increase over losses of $(3.28) per share from the same period last year. The company reported quarterly sales of $1.09 million which beat the analyst consensus estimate of $890.00 thousand by 22.36 percent. This is a 24.74 percent increase over sales of $873.00 thousand the same period last year.